|Mr. Punit S. Dhillon B.A., BA||CEO, Pres, Principal Accounting Officer, Sec. & Exec. Chairman||228.08k||N/A||1980|
|Ms. Kaitlyn Melanie Arsenault CPA||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Karam Takhar||VP of Corp. Devel. & Investor Relations||N/A||N/A||N/A|
|Mr. Tom Kim Esq.||Gen. Counsel & Director of IP||N/A||N/A||N/A|
|Mr. Tu Diep M.Sc.||Chief Devel. Officer||N/A||N/A||N/A|
|Ms. Rhea Williams M.P.H.||Head of Regulatory Affairs & Quality Assurance||N/A||N/A||N/A|
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based therapeutics for the treatment of infectious diseases. The company's lead product candidate is THCVHS, which is in preclinical trials for the treatment of glaucoma. It is also developing CBDVHS that is in preclinical trials to treat various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy; and Cannabinoid Cocktail for the treatment of anti-infective diseases. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Skye Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.